ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
Abstract ALK positive non-small cell lung cancer is highly responsive to ALK inhibitors such as crizotinib, but drug resistance typically develops within a year of treatment. In this study we investigated whether IGF-1R is an independent druggable target in ALK-positive lung cancer cells. We confirm...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/398999e043dc426f9106b6eb7c119b5d |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|